Open AccessQUAD shot: an effective cyclical hypofractionated palliative radiotherapy for salivary gland carcinoma
Author(s) -
Ryo Toya,
Tetsuo Saitô,
Tomohiko Matsuyama,
Takahiro Watakabe,
Kohsei Yamaguchi,
Daizo Murakami,
Yasuhiro Honda,
Sachiko Mizutari,
Yorihisa Orita,
Natsuo Oya
Publication year - 2020
Publication title -
bjr case reports
Language(s) - English
Resource type - Journals
ISSN - 2055-7159
DOI - 10.1259/bjrcr.20190132
Subject(s) - medicine , radiation therapy , regimen , salivary gland , parotid gland , stage (stratigraphy) , toxicity , oncology , radiology , pathology , paleontology , biology
Surgery with or without post-operative radiotherapy is the mainstay treatment for salivary gland carcinoma (SGC); however, palliative radiotherapy or supportive observation is considered for elderly patients. An 87-year-old female who was diagnosed with SGC in the left parotid gland, with a clinical stage T4aN2bM0 Stage IVA, underwent the Radiation Therapy Oncology Group 8502 “QUAD shot” regimen (14.8 Gy/4 fractions, twice-daily treatment with a 6 h interval, on 2 consecutive days), which were repeated every 4 weeks 3 times using volumetric modulated arc therapy. During and after the treatment, she experienced no acute toxicity but had Grade 1 xerostomia. At 4 months after completion of the treatment, [ 18 F]-fluoro-2-deoxy-D-glucose positron emission tomography/CT revealed a complete metabolic response to the treatment. She is still alive without any evidence of recurrence 9 months after completion of the treatment. The Radiation Therapy Oncology Group 8502 “QUAD shot” regimen using VMAT may be an effective palliative treatment for SGC with minimal toxicity.